European Pharmaceutical Review

AUGUST 22, 2022

Pharma contract manufacturing market to grow to $130bn by 2026… The post Trends in biopharma contract manufacturing 2022 appeared first on European Pharmaceutical Review.

Biopharma 98

Biopharma Manufacturing Marketing Competition 98

European Pharmaceutical Review

NOVEMBER 12, 2024

To boost AstraZeneca’s research and manufacturing footprint by the end of 2026, it is dedicating $3.5 Overall, the biopharma firm explained that these initial US investments are part of AstraZeneca’s plan to attain $80 billion in Total Revenue by the end of the decade. billion of capital investment in the US.

Manufacturing 59

Manufacturing Biopharma Healthcare Healthcare 59

European Pharmaceutical Review

JULY 21, 2023

The company intends to invest approximately $90 million at its site in Ljubljana, Slovenia, to establish a dedicated Sandoz Biopharma Development Center by 2026. To support future growth of its biosimilar pipeline, Sandoz is planning to build a Biosimilar Technical Development Center in Slovenia.

Biopharma 98

Biopharma Manufacturing Competition Healthcare 98

European Pharmaceutical Review

SEPTEMBER 11, 2023

This move would help to establish its Sandoz Biopharma Development Center by 2026, the company stated when the news was announced. In July 2023, Sandoz revealed that to support future development of its biosimilar pipeline, it planned to invest approximately $90 million at its site in Ljubljana, Slovenia.

Biopharma 96

Biopharma Manufacturing Medicine Safety 96

European Pharmaceutical Review

APRIL 18, 2023

GSK has agreed to acquire late-stage biopharma BELLUS Health, for a total of £1.6 Camlipixant is anticipated to gain regulatory approval and be launched in 2026. The proposed acquisition will give GSK access to camlipixant, a highly selective P2X3 antagonist for first-line treatment of adults with refractory chronic cough (RCC).

Biopharma 98

Biopharma Sales Patients Medical 98

European Pharmaceutical Review

NOVEMBER 15, 2023

In July, Sandoz shared that it planned to invest approximately $90 million at its European site in Ljubljana, Slovenia, to establish a dedicated Sandoz Biopharma Development Center by 2026. The company stated that the new site will create approximately 200 new full-time jobs once the facility is opened.

Medicine 93

Medicine Manufacturing Networking Biopharma 93

European Pharmaceutical Review

SEPTEMBER 15, 2023

CUBIC CRO Service Dr Ferrer Biopharma: GentleMist Technology IamFluidics B.V.: EPR are attending the event – let us know so our team can organise an interview with you or your company, or provide more information on opportunities such as sponsorship.

Pharma 119

Pharma Manufacturing Biopharma Pharmaceutical 119

Clarivate

OCTOBER 31, 2023

Plenty of biotech companies are happy to take a pharma deal presently to extend their financial runway into 2024, 2025, and 2026, said Williamson, “and if that means not retaining significant rights, so be it.” on making these steps a reality to ensure you create the best deal for your company and customers.

Pharma 52

Pharma Biopharma Marketing Healthcare 52

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Pharmaceutical Technology

JANUARY 31, 2023

Inflation Reduction Act Speaking during the keynote panel “FDA & ARPA-H: Life Sciences, Biopharma & Medtech Priorities in a New Year”, Califf discussed the Inflation Reduction Act of August 2022, which aims to lower prescription drug prices.

FDA 52

FDA Prescription Medicine Biopharma 52

Clarivate

APRIL 24, 2023

Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026. billion deal to acquire Oak Street Health, a value-based primary-care company focused on treating Medicare patients.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

Clarivate

AUGUST 20, 2024

Price negotiations will be staggered over time, beginning with this initial list of ten Part D drugs that takes effect in 2026 (Part D is the prescription drug coverage component of Medicare, a federal health insurance program for people 65 and older which covers nearly 1 in 5 Americans). These ten drugs cost Medicare Part D nearly $46.8

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52

Clarivate

OCTOBER 17, 2024

There are two ways telehealth waivers can be extended through 2025 – via The Centers for Medicare & Medicaid Rule and legislatively through 2026 via H.R. Other healthcare topics to watch: Telehealth About a dozen federal telehealth waivers put in place during the Covid pandemic are set to expire Dec.

Healthcare 52

Healthcare Healthcare Government Insurance 52